Coronary Disease - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 41

Coronary Disease – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Coronary Disease - Pipeline Review, H2 2012', provides an overview of the Coronary Disease therapeutic pipeline. This report provides information on the therapeutic development for Coronary Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Coronary Disease. 'Coronary Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Coronary Disease.
- A review of the Coronary Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Coronary Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Coronary Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Coronary Disease pipeline depth and focus of Coronary Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Coronary Disease Therapeutic Products under Development, Key Players in Coronary Disease Therapeutics, Coronary Disease Pipeline Overview, Coronary Disease Pipeline, Coronary Disease Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Coronary Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Coronary Disease 7
Coronary Disease Therapeutics under Development by Companies 9
Coronary Disease Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Coronary Disease Therapeutics – Products under Development by Companies 14
Coronary Disease Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Coronary Disease Therapeutics Development 16
CardioVascular BioTherapeutics, Inc. 16
Light Sciences Oncology, Inc. 17
Coronary Disease – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
CVBT-141H - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Aptocine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Simvastatin + Niacin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
FGF-1141 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Sodium Nitrite - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Coronary Disease Therapeutics – Drug Profile Updates 31
Coronary Disease Therapeutics – Discontinued Products 32
Coronary Disease Therapeutics - Dormant Products 33
Coronary Disease – Product Development Milestones 34
Featured News & Press Releases 34
Jun 22, 2012: Proteo Provides Update On Phase II Study Of Elafin In Coronary Bypass Surgery 34
May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib 34
Mar 28, 2012: Regado To Present Data On Anticoagulant System REG1 At Needham & Company’s 11th Annual Healthcare Conference 35
Aug 16, 2011: Proteo's EMPIRE-Study Recruits First Coronary Bypass Patients 35
Jan 21, 2011: AstraZeneca Replies To FDA Complete Response Letter For Ticagrelor Tablets 36
Jan 05, 2011: BioTime Subsidiary ReCyte Therapeutics, Inc. To Develop Therapies For Age-Related Cardiovascular And Blood Disorders 36
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 37
Jun 21, 2010: Pfizer Reports Caduet Reduces 10-Year Calculated Risk Of Coronary Heart Disease 37
May 12, 2010: Regeneron Provides Initial Data on REGN727 38
Mar 17, 2010: AstraZeneca Presents New PLATO Sub-Analysis Of CABG Patients At ACC 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Coronary Disease, H2 2012 7
Products under Development for Coronary Disease – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
CardioVascular BioTherapeutics, Inc., H2 2012 16
Light Sciences Oncology, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Coronary Disease Therapeutics – Drug Profile Updates 31
Coronary Disease Therapeutics – Discontinued Products 32
Coronary Disease Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Coronary Disease, H2 2012 7
Products under Development for Coronary Disease – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Customers who bought this item also bought

• Acute Coronary Syndrome - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Alzheimer's Disease - Pipeline Review, H2 2012